IBM’s AI Agent Push Faces a Crucial Earnings Check as Shares Rebound

IBM shares rally above 200-day moving average after unveiling 0.7nm Nanostack chip and $1B quantum funding, but consulting weakness and Confluent acquisition add scrutiny ahead of Q2 earnings.

IBM’s stock capped the week with a sharp rally, climbing nearly five percent on Friday to close at €237.80. The move pushed the shares back above their 200-day moving average at €235.90 — a technical milestone that had been acting as resistance. The RSI of 56 suggests the stock is neither overbought nor oversold, leaving room for further gains if momentum holds.

The catalyst behind the surge was twofold. On one hand, IBM unveiled its “Nanostack” prototype on June 25 — a 0.7-nanometer chip cramming 100 billion transistors onto a tiny die, promising a leap in computing power. On the other, the US government is poised to funnel $1 billion into a dedicated “Quantum Foundry” under the CHIPS Act, with a mandate to deliver a working quantum computer by 2028 and force federal agencies onto quantum-safe encryption by 2031. IBM is positioning itself at the centre of a market that is still in its infancy but rapidly accelerating.

Yet the real story this year has less to do with bleeding-edge hardware and more with autonomous AI agents. Gartner expects that by the end of 2026, 40 percent of all enterprise applications will integrate these agents — up from under five percent the year before. IBM is betting on a control layer that governs AI agents across multiple clouds, targeting regulated large customers willing to pay a premium for oversight. An internal study found that 82 percent of executives expect a multi-model approach by 2030, and companies with strict AI governance deploy 16 times more agents while spending less and earning higher margins.

That pitch has resonated with investors, but the consulting division — the channel through which many of these AI projects are sold — has been a weak spot. The market punished the stock in April despite strong cash flows, because consulting growth was sluggish. Around 30 percent of the consulting order book now involves generative AI, and the key question is whether those backlogs are converting into real revenue. Management is targeting software growth of at least ten percent for the full year, while consulting is expected to eke out only low single-digit gains.

The $11 billion acquisition of Confluent adds another layer of scrutiny. The real-time data tools fit neatly into IBM’s AI platform, but the company must demonstrate cross-selling success to justify the hefty premium.

Institutional investors have already voted with their wallets. Diamant Asset Management ballooned its stake by over 24,000 percent in the first quarter, while Cornerstone Wealth Group and Janney Montgomery Scott also added heavily. JPMorgan responded by upgrading the stock to “Overweight” with a $291 price target, noting that software now accounts for nearly half of IBM’s revenue.

The next major test arrives on July 22, when IBM reports second-quarter earnings. The bar is high: the company beat expectations in Q1 with earnings of $1.91 per share, but the market wants proof that the AI order books are translating into tangible sales — and a clear timeline for the quantum project. A close below the 200-day line after the report would be a damaging signal, reinforcing the stock’s year-to-date loss of more than four percent. On the upside, a clean break above the psychological €250 level would open the door to the average analyst target of roughly €258. With volatility running near 70 percent, the shares are primed for a big move either way.